S. Verma

933 total citations
21 papers, 691 citations indexed

About

S. Verma is a scholar working on Oncology, Economics and Econometrics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, S. Verma has authored 21 papers receiving a total of 691 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 8 papers in Economics and Econometrics and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in S. Verma's work include Cancer Treatment and Pharmacology (8 papers), Economic and Financial Impacts of Cancer (7 papers) and Breast Cancer Treatment Studies (5 papers). S. Verma is often cited by papers focused on Cancer Treatment and Pharmacology (8 papers), Economic and Financial Impacts of Cancer (7 papers) and Breast Cancer Treatment Studies (5 papers). S. Verma collaborates with scholars based in Canada, United States and Australia. S. Verma's co-authors include William K. Evans, Christel Le Petit, B P Will, Eva Tomiak, J.M. Berthelot, Ian Quirt, Joel Werier, Rita A. Kandel, Michelle Ghert and N. Coakley and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.

In The Last Decade

S. Verma

20 papers receiving 670 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S. Verma Canada 13 447 246 151 123 120 21 691
Feng Wen China 14 218 0.5× 206 0.8× 102 0.7× 131 1.1× 52 0.4× 53 699
Gordana Jovic United Kingdom 14 439 1.0× 544 2.2× 166 1.1× 81 0.7× 46 0.4× 30 1.1k
Michael W. Drazer United States 15 192 0.4× 278 1.1× 94 0.6× 121 1.0× 37 0.3× 38 769
Ewa Matczak United States 13 295 0.7× 384 1.6× 147 1.0× 282 2.3× 55 0.5× 24 866
Taizo Hirata Japan 12 555 1.2× 285 1.2× 145 1.0× 153 1.2× 46 0.4× 36 808
Elisabeth F.P. Peterse Netherlands 15 723 1.6× 361 1.5× 124 0.8× 204 1.7× 60 0.5× 28 1.0k
Roel J.W. van Kampen Netherlands 13 562 1.3× 283 1.2× 261 1.7× 118 1.0× 42 0.3× 18 891
Claudia Andreetta Italy 16 517 1.2× 205 0.8× 296 2.0× 162 1.3× 20 0.2× 41 831
Hamdy A. Azim Egypt 19 766 1.7× 352 1.4× 252 1.7× 230 1.9× 29 0.2× 66 1.1k
Christopher W. Lee Canada 14 520 1.2× 448 1.8× 82 0.5× 326 2.7× 41 0.3× 24 980

Countries citing papers authored by S. Verma

Since Specialization
Citations

This map shows the geographic impact of S. Verma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Verma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Verma more than expected).

Fields of papers citing papers by S. Verma

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Verma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Verma. The network helps show where S. Verma may publish in the future.

Co-authorship network of co-authors of S. Verma

This figure shows the co-authorship network connecting the top 25 collaborators of S. Verma. A scholar is included among the top collaborators of S. Verma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Verma. S. Verma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gorthi, Sankar Prasad, et al.. (2023). Step Ladder Expansive Cranioplasty: A Novel Perspective in Cranial Volume Augmentation Surgery. Asian Journal of Neurosurgery. 18(2). 414–419.
2.
Harbeck, Nadia, Shrividya Iyer, Nicholas C. Turner, et al.. (2016). Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial. Annals of Oncology. 27(6). 1047–1054. 114 indexed citations
3.
Arnaout, Angel, Iryna Kuchuk, Nathaniel Bouganim, et al.. (2016). Can the Referring Surgeon Enhance Accrual of Breast Cancer Patients to Medical and Radiation Oncology Trials? The Enhance Study. Current Oncology. 23(3). 276–279. 10 indexed citations
4.
Addison, Christina, Demetrios Simos, Gregory R. Pond, et al.. (2016). A phase 2 trial exploring the clinical and correlative effects of combining doxycycline with bone-targeted therapy in patients with metastatic breast cancer. Journal of bone oncology. 5(4). 173–179. 14 indexed citations
5.
Brackstone, Muriel, Glenn G. Fletcher, Ian S. Dayes, et al.. (2015). Locoregional Therapy of Locally Advanced Breast Cancer: A Clinical Practice Guideline. Current Oncology. 22(11). 54–66. 32 indexed citations
6.
Yao, Xiaomei, Tom Corbett, Abha A. Gupta, et al.. (2014). A Systematic Review of Active Treatment Options in Patients with Desmoid Tumours. Current Oncology. 21(4). 613–629. 24 indexed citations
7.
Kandel, Rita A., N. Coakley, Joel Werier, et al.. (2013). Surgical Margins and Handling of Soft-Tissue Sarcoma in Extremities: A Clinical Practice Guideline. Current Oncology. 20(3). 247–254. 77 indexed citations
8.
Petrella, Teresa M., S. Verma, Karen Spithoff, Ian Quirt, & David R. McCready. (2012). Adjuvant Interferon Therapy for Patients at High Risk for Recurrent Melanoma: An Updated Systematic Review and Practice Guideline. Clinical Oncology. 24(6). 413–423. 41 indexed citations
9.
Bernard, Lisa, et al.. (2011). A Canadian Economic Analysis of U.S. Oncology Adjuvant Trial 9735. Current Oncology. 18(2). 67–75. 6 indexed citations
10.
Mittmann, Nicole, et al.. (2010). Cost Effectiveness of tac versus fac in Adjuvant Treatment of Node-Positive Breast Cancer. Current Oncology. 17(1). 7–16. 24 indexed citations
11.
12.
Pivot, Xavier, S. Verma, Christoph Thomssen, et al.. (2009). Clinical benefit of bevacizumab (BV) plus first-line docetaxel (D) in elderly patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC): AVADO study. Journal of Clinical Oncology. 27(15_suppl). 1094–1094. 16 indexed citations
13.
Dent, Susan, Lisa Vandermeer, Johanna N. Spaans, et al.. (2007). Adjuvant trastuzumab (T) in early stage breast cancer (EBC): Is cardiac dysfunction (CD) clinically significant?. Journal of Clinical Oncology. 25(18_suppl). 11072–11072. 1 indexed citations
14.
15.
Verma, S., et al.. (2007). Central nervous system (CNS) metastases (mets) in HER2+ metastatic breast cancer (MBC) patients (pts): Patterns of relapse and impact on survival. Journal of Clinical Oncology. 25(18_suppl). 1017–1017. 5 indexed citations
16.
Cappelli, Mario, Linda Surh, Lauren Humphreys, et al.. (2001). Measuring women's preferences for breast cancer treatments and BRCA1/BRCA2 testing. Quality of Life Research. 10(7). 595–607. 33 indexed citations
17.
Will, B P, J.M. Berthelot, Christel Le Petit, et al.. (2000). Estimates of the lifetime costs of breast cancer treatment in Canada. European Journal of Cancer. 36(6). 724–735. 122 indexed citations
18.
Will, B P, et al.. (1999). Diagnostic and therapeutic approaches for nonmetastatic breast cancer in Canada, and their associated costs. British Journal of Cancer. 79(9-10). 1428–1436. 29 indexed citations
19.
Evans, W.K., et al.. (1997). PP20. Opportunities to reduce the cost of care for breast cancer (BC) in Canada. European Journal of Cancer. 33. S21–S22. 1 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Feng Wen Breakdown of academic impact, for papers by Gordana Jovic Breakdown of academic impact, for papers by Michael W. Drazer Breakdown of academic impact, for papers by Ewa Matczak Breakdown of academic impact, for papers by Taizo Hirata Breakdown of academic impact, for papers by Elisabeth F.P. Peterse Breakdown of academic impact, for papers by Roel J.W. van Kampen Breakdown of academic impact, for papers by Claudia Andreetta Breakdown of academic impact, for papers by Hamdy A. Azim Breakdown of academic impact, for papers by Christopher W. Lee
Rankless by CCL
2026